Literature DB >> 15927148

Limiting burn extension by transient inhibition of Connexin43 expression at the site of injury.

P Coutinho1, C Qiu, S Frank, C M Wang, T Brown, C R Green, D L Becker.   

Abstract

Extension of a burn wound over the first 24h following injury is recognised clinically, and leads to diagnostic and therapeutic dilemmas. In the central nervous system, a similar spread of damage, beyond the initial injury, can occur via the spread of death signals from injured cells to their healthy neighbours via Connexin43 (Cx43) gap junction channels. In the skin, Cx43 is expressed in the basal epidermis and in fibroblasts and dermal appendages. We have used Cx43 specific antisense oligodeoxynucleotide approach to transiently down-regulate Cx43 protein in the early stages of partial thickness cutaneous burn wound healing. Antisense ODNs reduce the spread of tissue damage and neutrophil infiltration around the wound following injury. Epithelial cell proliferation is increased and the rate of wound closure is accelerated, compared to controls. Resultant scarring is smaller with less granulation tissue and more dermal appendages than controls. These findings suggest that Cx43 antisense treatment speeds partial thickness burn wound healing and reduces scarring. We suggest that this approach may provide an effective adjunct to managing partial thickness burn wounds.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15927148     DOI: 10.1016/j.bjps.2004.12.022

Source DB:  PubMed          Journal:  Br J Plast Surg        ISSN: 0007-1226


  28 in total

Review 1.  Roles of gap junctions and connexins in non-neoplastic pathological processes in which cell proliferation is involved.

Authors:  Maria Lúcia Zaidan Dagli; Francisco Javier Hernandez-Blazquez
Journal:  J Membr Biol       Date:  2007-07-25       Impact factor: 1.843

2.  Connexin43 modulation inhibits scarring in a rabbit eye glaucoma trabeculectomy model.

Authors:  Narmadai C Deva; Jie Zhang; Colin R Green; Helen V Danesh-Meyer
Journal:  Inflammation       Date:  2012-08       Impact factor: 4.092

Review 3.  Cardiac to cancer: connecting connexins to clinical opportunity.

Authors:  Christina L Grek; J Matthew Rhett; Gautam S Ghatnekar
Journal:  FEBS Lett       Date:  2014-03-04       Impact factor: 4.124

4.  Connexin 43 regulates the expression of wound healing-related genes in human gingival and skin fibroblasts.

Authors:  Rana Tarzemany; Guoqiao Jiang; Jean X Jiang; Corrie Gallant-Behm; Colin Wiebe; David A Hart; Hannu Larjava; Lari Häkkinen
Journal:  Exp Cell Res       Date:  2018-03-27       Impact factor: 3.905

5.  In vitro optimization of antisense oligodeoxynucleotide design: an example using the connexin gene family.

Authors:  Lee Yong Law; Wei V Zhang; N Susan Stott; David L Becker; Colin R Green
Journal:  J Biomol Tech       Date:  2006-09

Review 6.  Therapeutic strategies targeting connexins.

Authors:  Dale W Laird; Paul D Lampe
Journal:  Nat Rev Drug Discov       Date:  2018-10-12       Impact factor: 84.694

7.  Tonabersat Prevents Inflammatory Damage in the Central Nervous System by Blocking Connexin43 Hemichannels.

Authors:  Yeri Kim; Jarred M Griffin; Mohd N Mat Nor; Jie Zhang; Peter S Freestone; Helen V Danesh-Meyer; Ilva D Rupenthal; Monica Acosta; Louise F B Nicholson; Simon J O'Carroll; Colin R Green
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

Review 8.  Connexins participate in the initiation and progression of atherosclerosis.

Authors:  Sandrine Morel; Laurent Burnier; Brenda R Kwak
Journal:  Semin Immunopathol       Date:  2009-04-30       Impact factor: 9.623

Review 9.  Embryonic wound healing: a primer for engineering novel therapies for tissue repair.

Authors:  Katherine E Degen; Robert G Gourdie
Journal:  Birth Defects Res C Embryo Today       Date:  2012-09

10.  Connexin43 carboxyl-terminal peptides reduce scar progenitor and promote regenerative healing following skin wounding.

Authors:  Gautam S Ghatnekar; Michael P O'Quinn; L Jane Jourdan; Abhijit A Gurjarpadhye; Robert L Draughn; Robert G Gourdie
Journal:  Regen Med       Date:  2009-03       Impact factor: 3.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.